Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by AletLeBainson Dec 19, 2019 10:35am

203 Views

Post# 30472362

Support from Zenith´s PR

Seems that Zenith´s PR from today helps RVX SP at current level:

Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
https://web.tmxmoney.com/article.php?newsid=5099909854083151&qm_symbol=RVX

If I recall it correctly Zenith was a spin out from RVX. But does RVX still have a stake in Zenith of XYZ %? Or are they 100% completely different companies now?

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading